PFIZER, ALLERGAN CONSIDERING MERGER

New Delhi, Medicare News, May 15, 2016

Drugmakers Pfizer and Allergan are considering combining in what could be the biggest merger in the healthcare industry in already busy year, the Wall Street Journal said on Wednesday.

Pfizer recently approached Botox-maker Allergan about a deal, the Journal said, citing people familiar with the matter.

“The process is in its early stages, and may not yield an agreement, while other details of the talks are unclear,” the report said.

Reuters was not immediately able to confirm the report.
The healthcare sector has seen an unprecedented wave of deals since early 2014, from large drugmakers buying up smaller rivals, to consolidation among makers of generic medicines and tie-ups between insurers.

Pfizer, which has a market value of about $219 billion, has already played a part in the recent deal frenzy, having last month paid $15 billion to acquire US rival Hospira.

The US-based company was not immediately available for comment.
Ireland-based Allergan, which declined to comment, has a market capitalization of about $113 billion. The company became the third-largest generic drug maker in the United States after combining with Actavis in March.

Both Pfizer and Allergan’s shares were little changed after the bell on Wednesday.
New York-based Pfizer, known for such medicines as Lipitor and Viagra, went after a much bigger target last year when it unsuccessfully pursued a $118 billion combination with Anglo-Swedish pharmaceuticals group AstraZeneca.
“That deal would have allowed Pfizer to lower its tax bill by moving its headquarters to England. A takeover of Dublin-based Allergan could have similar advantages for Pfizer,” the Wall Street Journal reported.

“When you’re the size of Pfizer, an acquisition like this may be the only choice you have in order to be able to move the needle for sequential growth…so the question now becomes, if not this, what, and if not now, when?” said WBB Securities’ analyst Stephen Brozak.

Allergan would give Pfizer, whose revenues are expected to slide 3.3 per cent this year, a boost in top-line growth. The Botox-maker’s revenue is seen increasing 39 per cent this year, according to Thomson Reuters I/B/E/S estimates, although much of that growth is thanks to the Actavis deal.
Following the Actavis tie-up, Allergan sold its generic drugs business to Israel’s Teva Pharmaceutical Industries in J

Related Posts

‘A Knight in Shining Armor’ packed a punch in FOGSI for Gender Equality

New Delhi: There was no fog in sight; FOGSI was shining as never before, thanks to the leadership of its outgoing president Dr Hrishikesh Pai. The over 40, 000 strong…

  • News
  • December 16, 2023
  • 8 views
Women are on Trajectory to make Presence Felt in Healthcare India

New Delhi: It could be advantage patients in times to come as women as workforce are increasing in healthcare domain of India. It is given that women power blended with…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Spurious drugs: Maiden Pharma blacklisted, all contracts cancelled

Spurious drugs: Maiden Pharma blacklisted, all contracts cancelled

DCC Calls For Strict Implementation Of Revised Schedule M, State-Level Activities To Address AMR

DCC Calls For Strict Implementation Of Revised Schedule M, State-Level Activities To Address AMR

Sanofi, Cipla Join Hands To Expand Reach Of CNS Portfolio In India

Sanofi, Cipla Join Hands To Expand Reach Of CNS Portfolio In India

Cyberabad Police Seize 1 Kg Alprazolam, Arrest Three

Cyberabad Police Seize 1 Kg Alprazolam, Arrest Three

Lee Health develops natural capsule for effective Heart care

Lee Health develops natural capsule for effective Heart care

Medical Shop Run By Twenty20 In Kizhakkambalam Asked To Shut Down

Medical Shop Run By Twenty20 In Kizhakkambalam Asked To Shut Down